Skip to main content
SpringerLink
Log in
Book cover

History of Vaccine Development pp 65–72Cite as

Vaccination Against Typhoid Fever: A Century of Research. End of the Beginning or Beginning of the End?

  • Chapter
  • First Online:

  • 3957 Accesses

Abstract

As its name implies, typhoid fever is a septicemic illness associated with alteration in consciousness (the Greek word “typhos” means “stupor”). It is cause by the Gram-negative bacillus Salmonella typhi which belongs to the enterobacteriaceae family. In its untreated form, the disease is marked by increasing fever, headache, insomnia, and general malaise. More serious complications include intestinal ­perforations and bleeding, severe alteration in consciousness, and possibly shock, which can be fatal. Similar but usually less severe cases, called paratyphoid fever, are caused by Salmonella paratyphi A, B, and C. Together, S. typhi and S. paratyphi infections are referred to as enteric fevers.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   229.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Louis PCA, Recherches antomiques, pathlogogiques, thérapeutiques, sur la maladie connue sous le nom de gastroentérite, fièvre putride, a dynamique, typhoïde, etc, compareé avec les maladies aiguës les plus ordinaries. Paris: JB Baillière, 1829

    Google Scholar 

  2. Bretonneau P. Notice sur la contagion de la dothinentérie. Arch Gen Méd 1829; 21:57

    Google Scholar 

  3. Budd W. Typhoid fever: its nature, mode of spreading, and prevention. London: Longmans, 1873

    Google Scholar 

  4. Eberth CJ. Organisms present in the organs during abdominal lymphoid infection. Virchows Arch Path Anat 1880; 58:74–81

    Google Scholar 

  5. Gaffky G. On the etiology of abdominal typhoid infection. Berlin: Mitteilungen aus dem ­kaiserlichen Gesundheitsamte 1884;2: 372–420

    Google Scholar 

  6. Widal GFI, Sicard A. Rescherche de la reaction aggluntinate dans le sang et le sérum desséchés typhiques et dans la sérosité des vésications. Bull Soc Méd Paris (3rd ser) 1896;13:681–682

    Google Scholar 

  7. Gröschel DHM, Hornick RB. Who introduced typhoid vaccinations: Almoth Wright or Richard Pfieffer? Rev Infect Dis 1981;6:1251–1254

    Article  Google Scholar 

  8. Wright AE. On the association of serous hemorrhages with conditions of defective blood-coagulopathy. Lancet 1896; 2:807–809

    Article  Google Scholar 

  9. Wright AE, Semple D. Remarks on vaccination against typhoid fever. Br Med J 1897;1:256–259

    Article  PubMed  CAS  Google Scholar 

  10. Pfieffer R, Kolle W. Experimentelle Untersuchungen zur Frage der Schutzimpfung des Menschen gegen Typhus abdominalis. Disch Med Wochenschr 1896;22:735–737

    Article  Google Scholar 

  11. Friedberger E. Zur Frage der Typhus-intestinalis Choleraschuzimpfung. Z Immunol 1919; 28:119–185

    Google Scholar 

  12. Yugoslavia Typhoid Commission. A controlled field trial of the effectiveness of acetone-dried and inactivated and heat-phenol activated typhoid vaccines in Yugoslavia. Bull WHO 1964; 30:623–630

    Google Scholar 

  13. Felix A, Pitt RB. A new antigen of Bacillus typhosus. Its relation to virulence and to active and passive immunization. Lancet 1932; ii:186–191

    Google Scholar 

  14. Webster ME, Landy M, Freeman ME. Studies on Vi antigen. II. Purification of Vi antigen from Escherichia coli 5396–38. J Immunol 1952; 69:135–142

    Google Scholar 

  15. Landy M. Studies on Vi antigens: immunization of human beings with purified Vi antigen. Am J Hyg 1954; 60:52–62

    PubMed  CAS  Google Scholar 

  16. Wong WH, Feeley JC. Isolation of Vi antigen and a simple method for its measurement. Appl Microbiol 1972; 24:28–33

    Google Scholar 

  17. Tacket CO, Ferriccio C, Robbins J. Safety and immunogenicity of the Salmonella typhi Vi capsular polysaccharide vaccines. J Infect Dis 1986; 154:342–345

    Article  PubMed  CAS  Google Scholar 

  18. Acharya IL, Lowe CU, Thapa RL. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. N Engl J Med 1987;18:1101–1104

    Article  Google Scholar 

  19. Klugman KP, Gilbertson IT, Koornhof HJ. Protective activity of Vi polysaccharide vaccine against typhoid fever. Lancet 1987; ii: 1165–1169

    Google Scholar 

  20. Szu SC, Li X, Schneerson R. Comparative immunigenicities of Vi polysaccharide-protein conjugates composed of cholera toxin or its B subunit as a carrier bound to high- or lower-molecular weight Vi. Infect Immun 1989; 57:3823–3827

    PubMed  CAS  Google Scholar 

  21. Germanier R, Furer E. Isolation and characterization of galE mutant Ty21a, of Salmonella typhi: a candidate strain for live oral typhoid vaccine. J Infect Dis 1975; 141:553–558

    Article  Google Scholar 

  22. Levine MM, Taylor DN, Ferriccio C. Typhoid vaccines come to age. Pediat Infect Dis 1989; 8:374–381

    Article  CAS  Google Scholar 

  23. Wahdan MH, Serie C, Cerisier Y. A controlled field trial of live Salmonella typhi strain Ty21a oral vaccine against typhoid: three year results. J Infect Dis 1982; 145:292–295

    Article  PubMed  CAS  Google Scholar 

  24. Levin MM, Ferriccio C, Black RE. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet 1987; i: 1049–1052

    Google Scholar 

  25. Levin MM, Ferreccio C, Cryz S, Ortiz E. Comparison of enteric-coated capsules and liquid formulation of Ty21a a typhoid vaccine in a randomized controlled field trial. Lancet 1990; 336:891–894

    Article  Google Scholar 

  26. Ivanoff B, Levine MM, Lambert PH. Vaccination against typhoid fever: present status. Bull WHO 1994; 72:954–971

    Google Scholar 

  27. Tacket CO, Hone DM, Losonsky G. Clinical acceptability and immunogenicity of CVD908 Salmonella typhi vaccine strain. Vaccine 1992; 10:443–446

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unité de Pathogénie Microbienne Moléculaire, INSERM U389, Institut Pasteur, 28 rue du Docteur-Roux, 75724, Paris, France

    Philippe Sansonetti

Authors
  1. Philippe Sansonetti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philippe Sansonetti .

Editor information

Editors and Affiliations

  1. , Emeritus Professor of Pediatrics, University of Pennsylvania, Philadelphia, 19104, Pennsylvania, USA

    Stanley A. Plotkin

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Sansonetti, P. (2011). Vaccination Against Typhoid Fever: A Century of Research. End of the Beginning or Beginning of the End?. In: Plotkin, S. (eds) History of Vaccine Development. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-1339-5_9

Download citation

Publish with us

Policies and ethics

Search

Navigation